Business Description
Cyclopharm Ltd
NAICS : 334510
SIC : 3845
ISIN : AU000000CYC5
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.77 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -1.31 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 7.06 | |||||
Beneish M-Score | -2.65 | |||||
WACC vs ROIC |
Growth Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.9 | |||||
3-Year EBITDA Growth Rate | 18.2 | |||||
3-Year EPS without NRI Growth Rate | 13.6 | |||||
3-Year FCF Growth Rate | 12.5 | |||||
3-Year Book Growth Rate | 17.2 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 74.42 | |||||
9-Day RSI | 62.85 | |||||
14-Day RSI | 56.18 | |||||
6-1 Month Momentum % | -21.24 | |||||
12-1 Month Momentum % | -14.42 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.48 | |||||
Quick Ratio | 2.32 | |||||
Cash Ratio | 1.35 | |||||
Days Inventory | 314.86 | |||||
Days Sales Outstanding | 96.7 | |||||
Days Payable | 177.39 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.57 | |||||
Forward Dividend Yield % | 0.57 | |||||
5-Year Yield-on-Cost % | 0.57 | |||||
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | 0.66 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 61.07 | |||||
Operating Margin % | -38.06 | |||||
Net Margin % | -17.85 | |||||
FCF Margin % | -29.37 | |||||
ROE % | -13.6 | |||||
ROA % | -9.74 | |||||
ROIC % | -45.71 | |||||
ROC (Joel Greenblatt) % | -27.24 | |||||
ROCE % | -10.52 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 6.38 | |||||
PB Ratio | 5.28 | |||||
Price-to-Tangible-Book | 6.43 | |||||
EV-to-EBIT | -38.89 | |||||
EV-to-EBITDA | -50.22 | |||||
EV-to-Revenue | 6.15 | |||||
EV-to-Forward-Revenue | 6.66 | |||||
EV-to-FCF | -20.46 | |||||
Price-to-Median-PS-Value | 1.13 | |||||
Price-to-Net-Current-Asset-Value | 10 | |||||
Earnings Yield (Greenblatt) % | -2.57 | |||||
FCF Yield % | -4.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cyclopharm Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | 26.339 | ||
EPS (TTM) (A$) | -0.051 | ||
Beta | 1.09 | ||
Volatility % | 42.29 | ||
14-Day RSI | 56.18 | ||
14-Day ATR (A$) | 0.020903 | ||
20-Day SMA (A$) | 1.77525 | ||
12-1 Month Momentum % | -14.42 | ||
52-Week Range (A$) | 1.715 - 3.15 | ||
Shares Outstanding (Mil) | 94.19 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cyclopharm Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cyclopharm Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Cyclopharm Ltd Frequently Asked Questions
What is Cyclopharm Ltd(ASX:CYC)'s stock price today?
When is next earnings date of Cyclopharm Ltd(ASX:CYC)?
Does Cyclopharm Ltd(ASX:CYC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |